JNJ — Johnson & Johnson
$263.81-1.42%
Last close: · regular session
After-hours $263.16 -0.25% ·
Last 60 sessions
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for JNJ in the TickerWise workspace.
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Company profile
- Sector: Healthcare
- Industry: Drug Manufacturers - General
- Country: US
- Exchange: NYSE
- Employees: 138,100
- Website: https://www.jnj.com
Latest SEC filings for JNJ
Latest JNJ news
- Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy? Read article
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk localised or locally advanced prostate cancer Read article
- NANOBIOTIX Announces Final Data from Phase 1 Study Evaluating JNJ-1900 (NBTXR3) With Immune Checkpoint Inhibitors as a 2L+ Therapy in Anti-PD-1-Resistant Primary Cutaneous Melanoma Read article
- NANOBIOTIX annonce les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) en combinaison avec des inhibiteurs de points de contrôle immunitaires chez des patients atteints de mélanome cutané résistant aux anti-PD-1, en traitement de deuxième ligne ou plus Read article
- CHMP empfiehlt die Zulassung von Johnson & Johnsons TALVEY®▼ (Talquetamab) plus Daratumumab zur Behandlung des rezidivierten/refraktären multiplen Myeloms in einer früheren Therapielinie Read article
- Le CHMP recommande l’approbation de TALVEY®▼ (talquetamab) de Johnson & Johnson, en association avec le daratumumab, dans une ligne de traitement plus précoce du myélome multiple en rechute/réfractaire Read article
- Il CHMP raccomanda l'approvazione di TALVEY®▼ (talquetamab) di Johnson & Johnson in combinazione con daratumumab nel trattamento in una linea terapeutica più precoce del mieloma multiplo recidivante/refrattario Read article
- Not Lilly. Not Johnson & Johnson. This Stock Will Be the Biggest Healthcare Winner of 2026 Read article
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.